Natixis Arvinas, Inc. Transaction History

Natixis

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 12, 2023	SELL	$26.15 - $37.26 $2,431 - $3,465	-93 Reduced 5.84%	1,499 $40,000
Q4 2022 Feb 24, 2023	BUY	$32.47 - $57.24 $51,692 - $91,126	1,592 New	1,592 $54,000
Q4 2021 Feb 14, 2022	SELL	$65.85 - $96.21 $1.55 Million - $2.27 Million	-23,600 Closed	0 $0
Q3 2021 Nov 12, 2021	BUY	$73.2 - $107.87 $1.73 Million - $2.55 Million	23,600 New	23,600 $1.94 Million

224

70.9M

1.52M

346K

Ticker ARVN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 53,205,300
Market Cap $986M
Description
Arvinas, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. Its lead product candidates include Bavdegalutamide, a proteolysis targeting chimera (PROTAC) protein degrader that is in phase I clinical trial targeting the androgen receptor ...

Get notified when there are updates to the investment portfolio of Natixis, based on Form 13F filings with the SEC.

Stay updated on Natixis with notifications on news.